E-viri
Recenzirano
Odprti dostop
-
Kilickap, Saadettin; Ozturk, Akin; Karadurmus, Nuri; Korkmaz, Taner; Yumuk, Perran Fulden; Cicin, Irfan; Paydas, Semra; Cilbir, Ebru; Sakalar, Teoman; Uysal, Mukremin; Yesil Cinkir, Havva; Uskent, Necdet; Demir, Necla; Sakin, Abdullah; Dursun, Oldac Uras; Aver, Birkan; Turhal, Nazim Serdar; Keskin, Serkan; Tural, Deniz; Eralp, Yesim; Bugdayci Basal, Fatma; Yasar, Hatime Arzu; Sendur, Mehmet Ali Nahit; Demirci, Umut; Cubukcu, Erdem; Karaagac, Mustafa; Cakar, Burcu; Tatli, Ali Murat; Yetisyigit, Tarkan; Urvay, Semiha; Gursoy, Pinar; Oyan, Basak; Turna, Zeynep Hande; Isikdogan, Abdurrahman; Olmez, Omer Fatih; Yazici, Ozan; Cabuk, Devrim; Seker, Mehmet Metin; Unal, Olcun Umit; Meydan, Nezih; Okutur, Sadi Kerem; Tunali, Didem; Erman, Mustafa
Medicine (Baltimore), 2024-May-24, 2024-05-24, 20240524, Letnik: 103, Številka: 21Journal Article
To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study evaluated demographic, clinical, and radiological imaging features, and treatment approaches in patients treated between 2013-2017. Totally 367 patients (54.8% males, median age at diagnosis 54 years) were included. Of them, 45.4% were smokers, and 8.7% had a family history of lung cancer. On radiological findings, 55.9% of the tumors were located peripherally, 7.7% of the patients had cavitary lesions, and 42.9% presented with pleural effusion. Pleural effusion was higher in nonsmokers than in smokers (37.3% vs. 25.3%, P = .018). About 47.4% of cases developed distant metastases during treatment, most frequently to the brain (26.2%). Chemotherapy was the first line treatment in 55.0%. Objective response rate was 61.9% (complete response: 7.6%; partial response: 54.2%). The highest complete and partial response rates were observed in patients who received crizotinib as the 2nd line treatment. The median progression-free survival was 14 months (standard error: 1.4, 95% confidence interval: 11.2-16.8 months). Crizotinib treatment lines yielded similar progression-free survival (P = .078). The most frequent treatment-related adverse event was fatigue (14.7%). Adrenal gland metastasis was significantly higher in males and smokers, and pleural involvement and effusion were significantly higher in nonsmokers-a novel finding that has not been reported previously. The radiological and histological characteristics were consistent with the literature data, but several differences in clinical characteristics might be related to population characteristics.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.